Insider buying last 90 days
No open-market insider purchases were filed for DHR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every DHR insider filing, plotted on the chart in Gekko.Open DHR in Gekko
Gekko Brief
AI summaryNov 4 closeDanaher's week centers on regulatory and strategic news in its diagnostics business. FDA clearance for Beckman Coulter Diagnostics' Access MeMed BV rapid assay, a test distinguishing bacterial from viral infections, drew fresh attention following what was described as strong third-quarter 2026 sales and net income. Danaher is also sponsoring a World Sepsis Congress satellite session on precision diagnostics, and new CEO Julie Sawyer Montgomery is set to present at the UBS Global Healthcare Conference on November 9 and the Jefferies Global Healthcare Conference on November 17. Separately, Argus updated its price target for Danaher to $260.
The stock closed at $234.93, up 2.1%, and sits above both its 50-day average of $219.71 and 200-day average of $201.03, with the shorter average above the longer one. The GekkoIndex reads 53.5, placing it in the Neutral zone, up 1.6 over five days. Price sits 3.6% above Gekko Fair Value of $226.79. One-month return stands at 9%, three-month at 17.5%, and six-month at 34.3%.
The next earnings date is 27 January 2027, 83 days away, placing it outside a typical 20-trading-day hold. No insider, Congress, or unusual options activity appears in the current windows. Six billionaire holders and three trailblazer holders are noted. Seasonality over the next 20 trading days has averaged a 5.5% return across 5 years, rising in 4 of them. Analyst coverage from 13 firms is entirely rated buy, with a consensus target of $259.90.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Danaher price vs fair value
Close $234.93200-day averageGekko Fair Value $226.79
Danaher quick facts
- Market cap
- $165.2B
- P/E ratio
- 37.7
- Forward P/E
- 24.9
- EPS, TTM
- $6.04
- Revenue, TTM
- $25.61B
- Profit margin
- 16.9%
- Dividend yield
- 0.65%
- Beta
- 0.80
- Volume
- 3.05M avg 4.39M
- 1-year return
- +9.7%
- Typical daily move
- ±2.9%
- Typical 20-day move
- ±4.6%
- 50-day average
- $219.71
- 200-day average
- $201.03
- Next earnings
- Jan 27 before open
- Shares outstanding
- 703.0M
Danaher swing-trade checklist
Danaher scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $234.93 is above the 50-day ($219.71) and 200-day ($201.03) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
53.5, Neutral
Reading 53.5 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
3.6% above
Price is within 5% of Gekko Fair Value (3.6% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 83 days
Next report Jan 27, 2027, 83 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+5.5% on average
From this point in the calendar, the next 20 trading days averaged +5.5% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Danaher stock chart and price history
Danaher closed at $234.93 on Nov 4, 2026, +9.7% over the past year, inside a 52-week range of $160.93 to $242.80.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +9.0%
- 3 months
- +17.5%
- 6 months
- +34.3%
- 1 year
- +9.7%
The full DHR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DHR in Gekko
Follow Danaher through every session
Put DHR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track DHR in GekkoFree for 7 days. No credit card required.
About Danaher
Danaher makes and distributes scientific, medical, industrial and commercial products and services on a global scale, working across science and technology fields rather than a single product line. It is best known for grouping this work into instruments, consumables and related services that support research, healthcare diagnosis and resource management.
The company operates through three segments. Life Sciences covers instrumentation such as mass spectrometers, flow cytometry, genomics and lab automation equipment, centrifuges, particle analysis tools and microscopes, along with consumables tied to gene and cell therapy, bioprocessing, and filtration and purification systems; its customers include pharmaceutical and biopharmaceutical firms, food and beverage makers, medical and life sciences companies, universities, medical schools, research institutes and industrial manufacturers. Diagnostics supplies chemistry, immunoassay, microbiology, hematology, molecular, acute care and pathology systems, reagents, consumables, software and support to hospitals, physician offices, reference labs and other care settings. Environmental & Applied Solutions provides instruments, software, consumables and disinfection systems for treating and managing different water types, plus tools for color and appearance management, packaging quality, printing, marking, coding and traceability for consumer, pharmaceutical and industrial goods.
Danaher's shares are listed on the NYSE under the ticker DHR.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- danaher.com
Danaher GekkoIndex: the smart money zone
Danaher’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.5, in the Neutral zone, up 1.6 points over five sessions.
53.5Neutral
Up 1.6 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 48 | +1.0% | +2.9% | ||
| Accumulation | 226 | +0.1% | +0.6% | ||
| Neutral (current zone) | 402 | 0.0% | −0.6% | ||
| Distribution | 20 | −0.7% | +1.9% | ||
| Selling | 1 | Too few readings yet | |||
Average DHR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the DHR price, zone by zone.Track DHR in Gekko
Is Danaher stock overvalued? Gekko Fair Value
Danaher trades 3.6% above Gekko Fair Value of $226.79, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Danaher shares are worth, recalculated every trading day.
$226.79
Gekko Fair Value, Nov 4, 2026
3.6% above fair value · About fair value
At the end of Aug 2026 the price was 1.1% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open DHR in Gekko
Danaher insider and Congress trading
No open-market insider purchases were filed for Danaher, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in DHR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for DHR, plotted on the chart in Gekko.Open DHR in Gekko
Buybacks
Danaher has been buying back its own shares.
- Bought back, quarter ended Jun 26, 2026
- $885.0M
- As a share of market cap
- 0.54%
- Trailing four quarters
- $2.90B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
9of the funds Gekko tracks hold DHR.
4added3opened2trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Danaher earnings: next date and track record
Danaher reports on Jan 27, 2027, before the open (83 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Jan 27, 2027
Expected before the open, 83 days away
- EPS estimate
- $2.49
- Revenue estimate
- $7.49B
7 of 8reports beat the EPS estimate
±6.5%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 21, 2026 AI summary
- What they said
- Danaher's Q3 2026 earnings call introduced new CEO Julie Sawyer Montgomery, who outlined a strategic vision to accelerate core revenue growth and gain market share in Life Sciences and Diagnostics. Montgomery acknowledged that growth has not consistently reflected the portfolio's full potential and emphasized stronger execution going forward. The company's strategy centers on leveraging its Danaher Business System and cross-business collaboration across discovery, biotechnology, and diagnostics segments.
- Guidance
- No specific revenue targets or EPS guidance were provided in this excerpt. Management focused on qualitative objectives: accelerating sustainable core revenue growth, more consistent share gains, and improved translation of portfolio strength into differentiated financial performance.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 21, 2026 | $2.11 est $1.92 | $6.55B est $6.56B | +2.5% |
| Jul 21, 2026 | $1.94 est $1.84 | $6.27B est $6.12B | −10.9% |
| Apr 21, 2026 | $2.06 est $1.94 | $5.95B est $5.98B | −5.9% |
| Jan 28, 2026 | $2.23 est $2.19 | $6.84B est $6.81B | −6.8% |
| Oct 21, 2025 | $1.89 est $1.72 | $6.05B est $6.00B | +4.7% |
| Jul 22, 2025 | $1.80 est $1.64 | $5.94B est $5.84B | +5.2% |
| Apr 22, 2025 | $1.88 est $1.63 | $5.74B est $5.57B | +6.1% |
| Jan 29, 2025 | $2.14 est $2.14 | $6.54B est $6.45B | −10.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Danaher stock forecast and analyst price targets
Analysts’ average 12-month price target for Danaher is $259.90, +10.6% from the last close, from 13 firms rating the stock in the last 90 days.
$259.90consensus 12-month target, +10.6% from the last close
Now $234.93Avg $259.90
Low $210High $275
Each firm’s latest rating in the last 90 days: 13 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 22 | Citi | $270 | +14.9% |
| Oct 22 | J.P. Morgan | $270 | +14.9% |
| Oct 22 | TD Cowen | $270 | +14.9% |
| Oct 22 | UBS | $260 | +10.7% |
| Oct 22 | Barclays | $260 | +10.7% |
−0.6%average 20-day move after past Neutral readings
+5.5%average move over the next 20 trading days in the last 5 years
±2.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Danaher seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Danaher averaged +5.5% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.6% | 2 of 5 |
| Next 10 trading days | +2.3% | 4 of 5 |
| Next 15 trading days | +5.4% | 4 of 5 |
| Next 20 trading days | +5.5% | 4 of 5 |
| Next 30 trading days | +4.0% | 4 of 5 |
For scale, DHR’s typical 20-trading-day move in either direction is about 4.6%.
Danaher market cap and key statistics
Danaher’s market cap is $165.2B, with a P/E ratio of 37.7 and revenue of $25.61B over the last twelve months.
Valuation
- Market cap
- $165.2B
- P/E ratio
- 37.7
- Forward P/E
- 24.9
- EPS, TTM
- $6.04
- Gekko Fair Value
- $226.79
Trading
- Volume
- 3.05M
- Avg volume, 20 days
- 4.39M
- 52-week high
- $242.80
- 52-week low
- $160.93
- Shares outstanding
- 703.0M
Financials
- Revenue, TTM
- $25.61B
- Profit margin
- 16.9%
- Return on equity
- 8.2%
- Quarterly earnings growth, YoY
- +37.8%
Risk and income
- Beta
- 0.80
- Typical daily move
- ±2.9%
- Typical 20-day move
- ±4.6%
- Dividend yield
- 0.65%
Danaher stock news this week
Coverage of Danaher this week reads positive: 10 positive, 10 neutral and 2 negative headlines.
- Danaher stock heads into November 4 sepsis diagnostics sessionad-hoc-news.de, Nov 4
- Learn Why The Bull Case For Danaher (DHR) Could Change Following FDA Test ClearanceYahoo Finance Singapore, Nov 4
- Danaher (DHR), Why Is It Drawing Fresh Attention Today?Yahoo Finance Singapore, Nov 4
- Danaher Corporation (DHER34.SA) Seasonal returns chart - Yahoo FinanceYahoo Finance Singapore, Nov 4
- Danaher Corporation (DHR) Stock forecastsYahoo Finance UK, Nov 4
- Danaher Corporation $DHR Shares Newly Purchased by Associated Banc CorpDefense World, Nov 4
Danaher peers
Danaher’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 14.5% above |
| ABTAbbott Laboratories | Distribution | 8.0% below |
| ISRGIntuitive Surgical | Distribution | 30.4% above |
| MDTMedtronic | Neutral | 16.0% below |
| SYKStryker | Distribution | 6.5% above |
| BSXBoston Scientific | Neutral | 26.8% below |
A peer links to its own page where one exists.
Danaher stock FAQ
What is Danaher’s market cap?
Danaher’s market cap is $165.2B at the Nov 4, 2026 close of $234.93, with 703.0M shares outstanding. The shares trade on a P/E ratio of 37.7.
What is the Danaher stock forecast?
The consensus analyst 12-month price target for Danaher is $259.90, +10.6% from the last close. Of the 13 firms that rated the stock in the last 90 days, 13 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Danaher stock overvalued or undervalued?
On Gekko’s estimate Danaher is about fair value: the Nov 4, 2026 close of $234.93 is 3.6% above Gekko Fair Value of $226.79. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Danaher report earnings next?
Danaher is expected to report on Jan 27, 2027, before the market opens (83 days away). Analysts expect earnings of $2.49 per share on revenue of $7.49B. Danaher beat the earnings estimate in 7 of its last 8 reports, moving 6.5% on average across the report.
What is Danaher’s 52-week high and low?
Danaher’s 52-week high is $242.80 and its 52-week low is $160.93; it closed at $234.93 on Nov 4, 2026, +9.7% over the past year. Over the last five years the shares peaked at $294.01 on Nov 30, 2021.
Is Danaher stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Danaher the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.